Sandoz and mAbxience agree on emicizumab biosimilar partnership

Sandoz and mAbxience have signed an agreement covering the licensing, development, manufacturing, and commercialisation of a proposed emicizumab biosimilar candidate. This candidate is intended to reference Hemlibra (emicizumab), a medicine used to treat haemophilia A, a genetic disorder. Haemophilia A is caused by insufficient or defective factor VIII and accounts for 80% of haemophilia cases worldwide. The reference medicine, Hemlibra, has estimated global sales of $5.7 billion. Under the agreement, mAbxience will develop and manufacture the biosimilar at its facilities in Argentina and Spain. Sandoz will receive exclusive global commercialisation rights, excluding Argentina, Paraguay, and Uruguay. The financial terms of the agreement were not disclosed. This deal marks the first haemophilia medicine in Sandoz’s biosimilar pipeline and expands mAbxience’s rare-disease portfolio.